It is reassuring that there is an increasing trend in CDK4/6i utilization annually from 7% in 2014 up to 24% by 2017, which later evaluations of our data may reflect.
← all excerpts
Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.
1
—
—